Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DBV Technologies S.A. (DBVT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret key information. DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy (EPIT) patches for food allergies and other immunologic conditions, and its filings offer detailed insight into this development activity.
Through Forms 8-K, DBV Technologies reports material events such as clinical milestones, financial results, equity offerings, and changes in corporate governance. Examples include announcements of positive topline results from the Phase 3 VITESSE trial of the Viaskin Peanut patch in peanut-allergic children aged 4 to 7 years, quarterly financial results, establishment of an at-the-market ADS offering program, and appointments or resignations of directors and senior leaders.
On this page, users can review filings related to results of operations and financial condition, other events, and board and executive changes, as disclosed under specific SEC items. For a Nasdaq-listed biopharmaceutical company like DBV Technologies, these documents help explain the status of its clinical programs, capital-raising activities, and governance structure.
Stock Titan enhances these filings with AI-generated summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each report. Real-time updates from the EDGAR system ensure that new DBV Technologies filings, including future 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, appear promptly as they are published. Users can also monitor disclosures that may relate to executive compensation, equity issuance, or other regulatory matters connected to the company’s Viaskin-based food allergy programs.
DBV Technologies S.A. (DBVT) received an updated ownership report on its ordinary shares, represented by American Depositary Shares. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 15,685,950 ordinary shares, or 5.7% of the class, based on 274,852,082 ordinary shares outstanding as of February 9, 2026.
Separately, Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC report beneficial ownership of 2,014,280 ordinary shares, or 0.7% of the class. The filing states the securities are not held for the purpose of changing or influencing control of DBV Technologies.
DBV Technologies S.A. received an updated Schedule 13G/A from a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of December 31, 2025, they collectively reported beneficial ownership of 14,350,960 Ordinary Shares, equal to 6.2% of the company’s Ordinary Shares.
The position consists of Ordinary Shares and American Depositary Shares, with each ADS representing five Ordinary Shares. The filing attributes control of the various Invus and Avicenna entities up a chain to Raymond Debbane, who may be deemed to beneficially own the same 6.2% stake. The group certifies the holdings are not for the purpose of changing or influencing control of DBV Technologies.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. reported that it issued a press release on January 16, 2026 announcing €166.7 million in gross proceeds from the full exercise of ABSA warrants and BS warrants that were issued in its March financing. This warrant exercise brings a substantial amount of new cash into the company. The press release, filed as Exhibit 99.1, provides further details on the transaction.
Baker Bros. Advisors and related entities report beneficial ownership of 25,586,190 ordinary shares of DBV Technologies S.A., equal to 9.99% of the class based on 254,000,000 ordinary shares outstanding as of January 12, 2026. All voting and dispositive power over these holdings is reported as sole, with no shared power.
The position includes ordinary shares plus pre-funded warrants and other warrants that can be exercised into additional ordinary shares, all subject to contractual beneficial ownership limits generally capped at 9.99%, with potential increases only after regulatory conditions and waiting periods. The filing also notes that on January 12, 2026, affiliated funds exercised certain warrants into long-dated pre-funded warrants expiring in 2035, and that director Michael Goller’s board-compensation warrants are treated as having pecuniary benefit for the Baker Bros. funds, not for him personally.
DBV Technologies S.A. insider filing shows major warrant restructuring by Baker Brothers–affiliated funds. On January 12, 2026, 667, L.P. and Baker Brothers Life Sciences, L.P. exercised 2,299,656 and 25,005,240 DBV Technologies BS Warrants at a strike price of EUR 1.5764, receiving an equal number of Second Pre-Funded Warrants. Each Second Pre-Funded Warrant is initially exercisable for 1.75 Ordinary Shares at an unpaid exercise price of EUR 0.01 per underlying share and may be exercised until April 7, 2035.
The Second Pre-Funded Warrants are subject to a “Second Pre-Funded Warrant Beneficial Ownership Limitation,” generally capping beneficial ownership at 9.99% of DBV’s outstanding Ordinary Shares, with potential increases up to 19.99% of shares and 24.99% of voting rights subject to regulatory conditions and a 61‑day waiting period. The transactions and resulting indirect pecuniary interests are reported for entities including 667, L.P., Baker Brothers Life Sciences, L.P., Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker, who disclaim beneficial ownership except to the extent of their pecuniary interests.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 20,469,392 shares of DBV Technologies S.A. common stock, representing 8.8% of the class as of the event date 12/31/2025. The firm reports no sole voting or dispositive power, but shared voting and shared dispositive power over all of these shares.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DBV Technologies. It also notes that interests of any single managed portfolio do not exceed 5% of the class of securities.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 20,469,392 shares of DBV Technologies S.A. common stock, representing 8.8% of the class as of the event date 12/31/2025. The firm reports no sole voting or dispositive power, but shared voting and shared dispositive power over all of these shares.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DBV Technologies. It also notes that interests of any single managed portfolio do not exceed 5% of the class of securities.
DBV Technologies S.A. received an updated Schedule 13D/A from a group of French public investment entities led by Bpifrance detailing their ownership of the company’s ordinary shares.
As of January 7, 2026, Bpifrance Participations directly holds 10,672,462 ordinary shares, or 4.6% of DBV Technologies’ outstanding ordinary shares, while Innobio directly holds 226,133 shares, or 0.1%. Through its ownership structure, Bpifrance, together with EPIC Bpifrance and Caisse des Depots, may be deemed to beneficially own 10,898,595 shares, or 4.7%, based on 232,047,938 ordinary shares outstanding as of December 31, 2025.
On January 5, 2026, Bpifrance Participations sold 86,777 ordinary shares in open-market transactions at a weighted average price of EUR3.02 per share. Due to these sales and exercises of warrants by various holders, Bpifrance Participations’ beneficial ownership fell below 5%, and this Amendment No. 10 is designated as a final, “exit” Schedule 13D filing for the reporting group.
DBV Technologies S.A. reported that it has issued a press release announcing positive topline results from its Phase 3 VITESSE trial of the VIASKIN Peanut Patch in peanut allergic children aged 4-7 years. This current report on Form 8-K attaches the full press release as an exhibit and incorporates it by reference.
The announcement marks a late-stage clinical milestone for the company’s peanut allergy program in young children. By formally furnishing the press release through the SEC, DBV signals that the Phase 3 VITESSE outcome for the VIASKIN Peanut Patch in 4- to 7-year-olds is an important development for its pipeline.